High Throughput Screening Identifies a Novel Compound Protecting Cardiomyocytes from Doxorubicin-Induced Damage

Figure 1

Screening for cardioprotective compounds. H9C2 cells were treated with test compounds (10 μM) for 30 min followed by a 24 h exposure to DOX (300 ng/mL). Viability was determined with the MTT assay. Percent cytoprotection is plotted so that only the most effective 15 compounds showing higher than 20% of cytoprotective effects appear as “hits.” (SD values are not shown due to the 3D presentation of data).